The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Issues in data monitoring and interim analysis of trials
Open accessAbstract
OBJECTIVES: To address issues about data monitoring committees (DMCs) for randomised controlled trials (RCTs). DATA SOURCES: Electronic databases. Handsearching of selected books. Personal contacts with experts in the field. REVIEW METHODS: Systematic literature reviews of DMCs and small group processes in decision-making; sample surveys of: reports of RCTs, recently completed and ongoing RCTs and policies of major organisations involved in RCTs; case studies of four DMCs; and interviews with experienced DMC members. All focused on 23 prestated questions. RESULTS: Although still a minority, RCTs increasingly have DMCs. There is wide agreement that nearly all trials need some form of data monitoring. Central to the role of the DMC is monitoring accumulating evidence related to benefit and toxicity; variation in emphasis has been reflected in the plethora of names. DMCs for trials performed for regulatory purposes should be aware of any special requirements and regulatory consequences. Advantages were identified for both larger and smaller DMCs. There is general agreement that a DMC should be independent and multidisciplinary. Consumer and ethicist membership is controversial. The chair is recognised as being particularly influential, and likely to be most effective if he or she is experienced, understands both statistical and clinical issues, and is facilitating in style and impartial. There is no evidence available to judge suggested approaches to training. The review suggested that costs should be covered, but other rewards must be so minimal as to not affect decision-making. It is usual to have a minimum frequency of DMC meetings, with evidence that face-to-face meetings are preferable. It is common to have open sessions and a closed session. A report to a DMC should cover benefits and risks in a balanced way, summarised in an accessible style, avoiding excessive detail, and be as current as possible. Disadvantages of blinded analyses seem to outweigh advantages. Information about comparable studies should be included, although interaction with the DMCs of similar ongoing trials is controversial. A range of formal statistical approaches can be used, although this is only one of a number of considerations. DMCs usually reach decisions by consensus, but other approaches are sometimes used. The general, but not unanimous, view is that DMCs should be advisory rather than executive on the basis that it is the trial organisers who are ultimately responsible for the conduct of the trial. CONCLUSIONS: Some form of data monitoring should be considered for all RCTs, with reasons given where there is no DMC or when any member is not independent. An early DMC meeting is helpful, determining roles and responsibilities; planned operations can be agreed with investigators and sponsors/funders. A template for a DMC charter is suggested. Competing interests should be declared. DMC size (commonly three to eight people) is chosen to optimise performance. Members are usually independent and drawn from appropriate backgrounds, and some, particularly the chair, are experienced. A minimum frequency of meetings is usually agreed, with flexibility for more if needed. The DMC should understand and agree the statistical approach (and guidelines) chosen, with both the DMC statistician and analysis statistician competent to apply the method. A DMC's primary purpose is to ensure that continuing a trial according to its protocol is ethical, taking account of both individual and collective ethics. A broader remit in respect of wider ethical issues is controversial; arguably, these are primarily the responsibility of research ethics committees, trial steering committees and investigators. The DMC should know the range of recommendations or decisions open to it, in advance. A record should be kept describing the key issues discussed and the rationale for decisions taken. Errors are likely to be reduced if a DMC makes a thorough review of the evidence and has a clear understanding of how it should function, there is active participation by all members, differences are resolved through discussion and there is systematic consideration of the various decision options. DMCs should be encouraged to comment on draft final trial reports. These should include information about the data monitoring process and detail the DMC membership. It is recommended that groups responsible for data monitoring be given the standard name 'Data Monitoring Committee' (DMC). Areas for further research include: widening DMC membership beyond clinicians, trialists and statisticians; initiatives to train DMC members; methods of DMC decision-making; 'open' data monitoring; DMCs covering a portfolio of trials rather than single trials; DMC size and membership, incorporating issues of group dynamics; empirical study of the workings of DMCs and their decision-making, and which trials should or should not have a DMC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Journal of the American Statistical Association
Koehler, A. B. (1995) · International Journal of Forecasting · doi:10.1016/0169-2070(95)90067-5 · Cited by 5,337
Studies of independence and conformity: I. A minority of one against a unanimous majority
Asch, S. E. (1956) · Psychological Monographs: General and Applied · doi:10.1037/h0093718 · Cited by 4,267
Decision making: A psychological analysis of conflict, choice, and commitment
(1978) · Evaluation and Program Planning · doi:10.1016/0149-7189(78)90042-3 · Cited by 3,946
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341802 · Cited by 3,638
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The theory of decision making.
Edwards, W. (1954) · Psychological Bulletin · doi:10.1037/h0053870 · Cited by 2,697
Consensus development methods, and their use in clinical guideline development.
Murphy, Black, Lamping, McKee, Sanderson, Askham, & Marteau (1998) · Health Technology Assessment · doi:10.3310/hta2030 · Cited by 2,051
Organizational behavior and human decision processes
Armstrong, J. S. (1988) · International Journal of Forecasting · doi:10.1016/0169-2070(88)90125-2 · Cited by 1,753
TEAMS IN ORGANIZATIONS: Recent Research on Performance and Effectiveness
Guzzo, R. A., & Dickson, M. W. (1996) · Annual Review of Psychology · doi:10.1146/annurev.psych.47.1.307 · Cited by 1,613
Group Sequential Methods with Applications to Clinical Trials
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC eBooks · doi:10.1201/9780367805326 · Cited by 1,336
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1550 · Cited by 1,255
The Framing of Decisions and the Psychology of Choice
Tversky, A., & Kahneman, D. (1985) · Behavioral Decision Making · doi:10.1007/978-1-4613-2391-4_2 · Cited by 1,252
Group polarization: A critical review and meta-analysis.
Isenberg, D. J. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.50.6.1141 · Cited by 1,044
Designing clinical research: An epidemiologic approach
(1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90023-8 · Cited by 948
Prospect Theory: An Analysis of Decision under Risk
Kahneman, D., & Tversky, A. (2000) · Choices, Values, and Frames · doi:10.1017/cbo9780511803475.003 · Cited by 922
On the Psychology of Judgment and Decision Making: (412982005-012)
Pious, S. (1993) · PsycEXTRA Dataset · doi:10.1037/e412982005-012 · Cited by 794
European Journal of Work and Organizational Psychology
(2020) · Psychology Press eBooks · doi:10.4324/9781003059707 · Cited by 618
Five Years of Groups Research: What We Have Learned and What Needs to Be Addressed
Bettenhausen, K. L. (1991) · Journal of Management · doi:10.1177/014920639101700205 · Cited by 541
Jury decision making: 45 years of empirical research on deliberating groups.
Devine, D. J., Clayton, L. D., Dunford, B. B., Seying, R., & Pryce, J. (2001) · Psychology Public Policy and Law · doi:10.1037//1076-8971.7.3.622 · Cited by 523
The Design and Analysis of Sequential Clinical Trials.
Whitehead, J. (1997) · Biometrics · doi:10.2307/2533535 · Cited by 516
Statistical Issues in Drug Development
Senn, S. (2007) · doi:10.1002/9780470723586 · Cited by 448
Alive and Well after 25 Years: A Review of Groupthink Research
Esser, J. K. (1998) · Organizational Behavior and Human Decision Processes · doi:10.1006/obhd.1998.2758 · Cited by 417
Factors that limit the quality, number and progress of randomised controlled trials
Prescott, Counsell, Gillespie, Grant, Russell, Kiauka, Colthart, Ross, Shepherd, & Russell (1999) · Health Technology Assessment · doi:10.3310/hta3200 · Cited by 390
Albanes, D., Heinonen, O., Huttunen, J., Taylor, P., Virtamo, J., Edwards, B., Haapakoski, J., Rautalahti, M., Hartman, A., & Palmgren, J. (1995) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/62.6.1427s · Cited by 379
Bayesian methods in health technology assessment: a review.
Spiegelhalter, Myles, Jones, & Abrams (2000) · Health Technology Assessment · doi:10.3310/hta4380 · Cited by 358
Oldham, P. D., & Armitage, P. (1976) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344357 · Cited by 343
Anscombe, F. J. (1963) · Journal of the American Statistical Association · doi:10.1080/01621459.1963.10500851 · Cited by 339
Monitoring clinical trials: Conditional or predictive power?
Spiegelhalter, D. J., Freedman, L. S., & Blackburn, P. R. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90003-6 · Cited by 307
Self-citationAldag, R. J., & Fuller, S. R. (1993) · Psychological Bulletin · doi:10.1037/0033-2909.113.3.533 · Cited by 306
The B-Value: A Tool for Monitoring Data
Lan, K. K. G., & Wittes, J. (1988) · Biometrics · doi:10.2307/2531870 · Cited by 303
Hidden impact of minorities: Fifteen years of minority influence research.
Maass, A., & Clark, R. D. (1984) · Psychological Bulletin · doi:10.1037/0033-2909.95.3.428 · Cited by 267
Clinical Trials: Design, Conduct, and Analysis
Baker, L. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390090119041 · Cited by 231
Proper analysis of the accuracy of group judgments.
Gigone, D., & Hastie, R. (1997) · Psychological Bulletin · doi:10.1037//0033-2909.121.1.149 · Cited by 215
Group sequential methods for clinical trials with a one-sided hypothesis
DEMETS, D. L., & WARE, J. H. (1980) · Biometrika · doi:10.1093/biomet/67.3.651 · Cited by 198
Conflict and performance in groups and organizations
Dreu, C. K. W. D., Harinck, F., & Vianen, A. E. M. V. (1999) · UvA-DARE (University of Amsterdam) · Cited by 197
Jones, P. E., & Roelofsma, P. H. M. P. (2000) · Ergonomics · doi:10.1080/00140130050084914 · Cited by 193
The effects of pretrial publicity on juror verdicts: A meta-analytic review.
Steblay, N. M., Besirevic, J., Fulero, S. M., & Jimenez-Lorente, B. (1999) · Law and Human Behavior · doi:10.1023/a:1022325019080 · Cited by 180
Leadership Effectiveness: An Integrative Review
Chemers, M. M. (2001) · Blackwell Handbook of Social Psychology: Group Processes · doi:10.1002/9780470998458.ch16 · Cited by 171
Investigating Therapies of Potentially Great Benefit: ECMO
Ware, J. H. (1989) · Statistical Science · doi:10.1214/ss/1177012384 · Cited by 170
Maier, N. R. F., & Solem, A. R. (1952) · Human Relations · doi:10.1177/001872675200500303 · Cited by 169
Ainsworth, S., Beresford, M., Milligan, D., Shaw, N., Matthews, J., Fenton, A., & Platt, M. W. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02136-x · Cited by 163
Repeated confidence intervals for group sequential clinical trials
Jennison, C., & Turnbull, B. W. (1984) · Controlled Clinical Trials · doi:10.1016/0197-2456(84)90148-x · Cited by 150
Moral Reasoning in Groups: Leaders Make a Difference
Dukerich, J. M., Nichols, M. L., Elm, D. R., & Vollrath, D. A. (1990) · Human Relations · doi:10.1177/001872679004300505 · Cited by 145
Monitoring of clinical trials: Issues and recommendations
Fleming, T. R., & DeMets, D. L. (1993) · Controlled Clinical Trials · doi:10.1016/0197-2456(93)90002-u · Cited by 141
Recasting Janis's Groupthink Model: The Key Role of Collective Efficacy in Decision Fiascoes
Whyte, G. (1998) · Organizational Behavior and Human Decision Processes · doi:10.1006/obhd.1998.2761 · Cited by 136
Group Decision Fiascoes Continue: Space Shuttle Challenger and a Revised Groupthink Framework
Moorhead, G., Ference, R., & Neck, C. P. (1991) · Human Relations · doi:10.1177/001872679104400601 · Cited by 130
Stopping rules and estimation problems in clinical trials
Hughes, M. D., & Pocock, S. (1988) · Statistics in Medicine · doi:10.1002/sim.4780071204 · Cited by 127
Self-citationTUTORIAL IN BIOSTATISTICS: BAYESIAN DATA MONITORING IN CLINICAL TRIALS
Fayers, P. M., Ashby, D., & Parmar, M. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19970630)16:12<1413::aid-sim578>3.0.co;2-u · Cited by 126
Self-citationThe agonising negative trend in monitoring of clinical trials
DeMets, D. L., Pocock, S. J., & Julian, D. G. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03464-9 · Cited by 126
Self-citationComparison of Bayesian with group sequential methods for monitoring clinical trials
Freedman, L. S., & Spiegelhalter, D. J. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90001-9 · Cited by 124
Self-citationEthical issues in the design and conduct of randomised controlled trials.
Edwards, Lilford, Braunholtz, Jackson, Hewison, & Thornton, V. (1998) · Health Technology Assessment · doi:10.3310/hta2150 · Cited by 124
Statistics and Medical Experimentation
Meier, P. (1975) · Biometrics · doi:10.2307/2529434 · Cited by 119
Trials stopped early: too good to be true?
Pocock, S., & White, I. R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)00379-1 · Cited by 113
Self-citationInterim analyses in clinical trials: Classical vs. bayesian approaches
Berry, D. A. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040412 · Cited by 112
Approaches for Optimal Sequential Decision Analysis in Clinical Trials
Carlin, B. P., Kadane, J. B., & Gelfand, A. E. (1998) · Biometrics · doi:10.2307/2533849 · Cited by 110
Freedman, L. S., Anderson, G. L., Kipnis, V., Prentice, R. L., Wang, C. Y., Rossouw, J. E., Wittes, J. T., & DeMets, D. L. (1996) · Controlled Clinical Trials · doi:10.1016/s0197-2456(96)00016-5 · Cited by 102
The what, why and how of bayesian clinical trials monitoring
Freedman, L. S., Spiegelhalter, D. J., & Parmar, M. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131312 · Cited by 101
Self-citationData Monitoring Committees in Clinical Trials: A Practical Perspective.
Grambsch, P. M. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00271-4 · Cited by 100
Personality and Work Behaviour
Robertson, I. T., & Callinan, M. (1998) · European Journal of Work and Organizational Psychology · doi:10.1080/135943298398736 · Cited by 96
Social processes and group decision making: anonymity in group decision support systems
Postmes, T., & Lea, M. (2000) · Ergonomics · doi:10.1080/00140130050084978 · Cited by 88
Practical aspects in data monitoring: A brief review
DeMets, D. L. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060706 · Cited by 88
Monitoring and Ensuring Safety During Clinical Research
Morse, M. A. (2001) · JAMA · doi:10.1001/jama.285.9.1201 · Cited by 87
Relating Cohesion to Stress, Strain, Disintegration, and Performance: An Organizing Framework
Griffith, J. E., & Vaitkus, M. A. (1999) · Military Psychology · doi:10.1207/s15327876mp1101_3 · Cited by 86
Neck, C. P., & Moorhead, G. (1995) · Human Relations · doi:10.1177/001872679504800505 · Cited by 82
Policies for study monitoring and interim reporting of results.
Green, S., Fleming, T. R., & O'Fallon, J. R. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.9.1477 · Cited by 81
Breaching or Building Social Boundaries? Side-Effects of Computer-Mediated Communication.
Postmes, T., Spears, R., & Lea, M. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 78
Moorhead, G., Neck, C. P., & West, M. (1998) · Organizational Behavior and Human Decision Processes · doi:10.1006/obhd.1998.2765 · Cited by 76
Statistical and ethical issues in monitoring clinical trials
Pocock, S. (1993) · Statistics in Medicine · doi:10.1002/sim.4780121512 · Cited by 75
Self-citationInterim analysis in clinical trials
Armitage, P. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100613 · Cited by 72
Modifying the design of ongoing trials without unblinding
Gould, A. L., & Shih, W. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980115)17:1<89::aid-sim730>3.0.co;2-d · Cited by 70
Guidelines for Monitoring Efficacy and Toxicity Responses in Clinical Trials
Cook, R. J., & Farewell, V. T. (1994) · Biometrics · doi:10.2307/2533451 · Cited by 69
Behind closed doors: The data monitoring board in randomized clinical trials
Wittes, J. T. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120504 · Cited by 65
Bayesian subset analysis in a colorectal cancer clinical trial
Dixon, D. O., & Simon, R. M. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110104 · Cited by 61
A Bayesian Test of Some Classical Hypotheses, with Applications to Sequential Clinical Trials
Cornfield, J. (1966) · Journal of the American Statistical Association · doi:10.2307/2282772 · Cited by 61
The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials
DeMets, D. L., Fleming, T. R., Whitley, R. J., Childress, J. F., Ellenberg, S. S., Foulkes, M. A., Mayer, K. H., O'Fallon, J. R., Pollard, R. B., Rahal, J. J., et al. (1995) · Controlled Clinical Trials · doi:10.1016/s0197-2456(95)00073-9 · Cited by 60
Masked Monitoring in Clinical Trials — Blind Stupidity?
Meinert, C. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805073381911 · Cited by 59
On the Allocation of Treatments in Sequential Medical Trials
Bather, J. A. (1985) · International Statistical Review · doi:10.2307/1402870 · Cited by 59
Data Monitoring Committees and Interim Monitoring Guidelines
Freidlin, B., Korn, E. L., & George, S. L. (1999) · Controlled Clinical Trials · doi:10.1016/s0197-2456(99)00017-3 · Cited by 57
Green, S., Benedetti, J., & Crowley, J. J. (1997) · Springer eBooks · doi:10.1007/978-1-4899-3352-2 · Cited by 50
Conformity and Independence in Groups: Majorities and Minorities
Martin, R., & Hewstone, M. (2001) · Wiley eBooks · doi:10.1002/9780470998458.ch9 · Cited by 49
Smith, M. A., Ungerleider, R. S., Korn, E. L., Rubinstein, L., & Simon, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2736 · Cited by 49
Progress In Small Group Research
Levine, J. (1990) · Annual Review of Psychology · doi:10.1146/annurev.psych.41.1.585 · Cited by 49
Randomised Controlled Clinical Trials
Bulpitt, C. J. (1983) · Springer eBooks · doi:10.1007/978-1-4757-6358-4 · Cited by 47
Clinical Trial Data and Safety Monitoring Boards
Armstrong, P. W., & Furberg, C. D. (1995) · Circulation · doi:10.1161/01.cir.91.3.901 · Cited by 46
Proschan, M. A., Follmann, D. A., & Geller, N. L. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131320 · Cited by 43
Formal approaches to safety monitoring of clinical trials in life-threatening conditions
Bolland, K., & Whitehead, J. (2000) · Statistics in Medicine · Cited by 42
Thompson, L. F., & Coovert, M. D. (2002) · Group Dynamics Theory Research and Practice · doi:10.1037/1089-2699.6.1.52 · Cited by 36
Monitoring clinical trials—interim data should be publicly available
Lilford, R. J., Braunholtz, D., Edwards, S., & Stevens, A. J. (2001) · BMJ · doi:10.1136/bmj.323.7310.441 · Cited by 35
Groupthink, Bay of Pigs, and Watergate Reconsidered
Raven, B. H. (1998) · Organizational Behavior and Human Decision Processes · doi:10.1006/obhd.1998.2766 · Cited by 35
A unified method for monitoring and analysing controlled trials
Grossman, J., Parmar, M., Spiegelhalter, D. J., & Freedman, L. S. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131804 · Cited by 34
Self-citationGroupthink: Deciding with the Leader and The Devil
Chen, Z., Lawson, R. B., Gordon, L. R., & McIntosh, B. R. (1996) · The Psychological Record · doi:10.1007/bf03395186 · Cited by 34
Termination of a randomized controlled trial of two vasectomy techniques
Chen-Mok, M., Bangdiwala, S. I., Dominik, R., Hays, M. A., Irsula, B., & Sokal, D. C. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00267-2 · Cited by 33
The NHLBI model: A 25 year history
Friedman, L. M. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120505 · Cited by 32
Early stopping rules ‐ clinical perspectives and ethical considerations
Baum, M., Houghton, J., & Abrams, K. R. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131322 · Cited by 32
Some practical aspects of the interim monitoring of clinical trials
Simon, R. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131315 · Cited by 31
Ellenberg, S. S., Myers, M. W., Blackwelder, W. C., & Hoth, D. F. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120510 · Cited by 30
Clinical Trials and Treatment Effects Monitoring
Meinert, C. L. (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(98)00027-0 · Cited by 30
On being the statistician on a Data and Safety Monitoring Board
Whitehead, J. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19991230)18:24<3425::aid-sim369>3.0.co;2-d · Cited by 30
Some FDA perspectives on data monitoring in clinical trials in drug development
O’Neill, R. T. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120529 · Cited by 30
Interim analyses, stopping rules and data monitoring in clinical trials in europe
Buyse, M. E. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120517 · Cited by 30
Design and analysis of clinical trials : concept and methodologies
Chow, S., & Liu, J. (1998) · Medical Entomology and Zoology · Cited by 29
META-ANALYSIS: CURRENT ISSUES IN RESEARCH SYNTHESIS
Olkin, I. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960630)15:12<1263::aid-sim305>3.0.co;2-k · Cited by 29
Sensitivity of Bayes Inference with Data-Dependent Stopping Rules
Rosenbaum, P. R., & Rubin, D. B. (1984) · The American Statistician · doi:10.1080/00031305.1984.10483176 · Cited by 29
Should local research ethics committees monitor research they have approved?
Pickworth, E. (2000) · Journal of Medical Ethics · doi:10.1136/jme.26.5.330 · Cited by 28
Data monitoring in clinical trials: The case for stochastic curtailment
Davis, B. R., & Hardy, R. J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90119-8 · Cited by 27
Group Decision Making in the Negative Domain
Hartman, S. J., & Nelson, B. H. (1996) · Group & Organization Management · doi:10.1177/1059601196212003 · Cited by 26
Data monitoring committees and capturing relevant information of high quality
Fleming, T. R. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120524 · Cited by 26
Should Data and Safety Monitoring Boards Share Confidential Interim Data?
Dixon, D. O., & Lagakos, S. W. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(99)00042-2 · Cited by 26
Groups over time: what are we really studying?
George, J. F., & Jessup, L. M. (1997) · International Journal of Human-Computer Studies · doi:10.1006/ijhc.1997.0135 · Cited by 24
The Dilemma of Threat: Group Effectiveness and Ineffectiveness Under Adversity
Turner, M. E., & Horvitz, T. (2014) · Psychology Press eBooks · doi:10.4324/9781315805986-26 · Cited by 24
Geller, N. L., & Stylianou, M. P. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120520 · Cited by 22
Toward a Process Theory of Groupthink
Mohamed, A. A., & Wiebe, F. A. (1996) · Small Group Research · doi:10.1177/1046496496273005 · Cited by 22
Liberati, A. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131326 · Cited by 21
Parmar, M., & Machin, D. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120515 · Cited by 21
Self-citationUse of spending functions for occasional or continuous monitoring of data in clinical trials
Lan, K. K. G., Rosenberger, W. F., & Lachin, J. M. (1993) · Statistics in Medicine · doi:10.1002/sim.4780122307 · Cited by 21
A survey of monitoring practices in cancer clinical trials
George, S. L. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120507 · Cited by 20
Data monitoring committees and early stopping guidelines: The southwest oncology group experience
Crowley, J. J., Green, S., Liu, P. Y., & Wolf, M. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131314 · Cited by 20
Sylvester, R. J., Bartelink, H. G. M. M., Rubens, R. D., & Eortc Breast Cancer Cooperative Group (1994) · Statistics in Medicine · doi:10.1002/sim.4780131306 · Cited by 20
Data monitoring committees: The moral case for maximum feasible independence
Walters, L. B. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120526 · Cited by 19
The case against independent monitoring committees
Harrington, D. P., Crowley, J. J., George, S. L., Pajak, T. F., Redmond, C. K., & Wieand, S. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131316 · Cited by 19
Procedures of Data and Safety Monitoring Committees
Pocock, S., & Furberg, C. D. (2001) · American Heart Journal · doi:10.1067/mhj.2001.113082 · Cited by 18
Self-citationShould all trials have a Data Safety and Monitoring Committee?
Cairns, J. A., Hallstrom, A. P., & Held, P. (2001) · American Heart Journal · doi:10.1067/mhj.2001.112501 · Cited by 18
Monitoring of clinical trials and interim analyses from a drug Sponsor's point of view
Williams, G. W., Davis, R. L., Getson, A. J., Gould, A. L., Hwang, I. K., Matthews, H., Shih, W. J., Snapinn, S. M., & Walton-Bowen, K. L. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120513 · Cited by 18
Interim Analyses: An Update of an FDA Reviewer’s Experience and Perspective
Sankoh, A. J. (1999) · Drug Information Journal · doi:10.1177/009286159903300120 · Cited by 17
Rockhold, F. W., & Enas, G. G. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120512 · Cited by 17
Role of external evidence in monitoring clinical trials: experience from a perinatal trial
Brocklehurst, P. (2000) · BMJ · doi:10.1136/bmj.320.7240.995 · Cited by 17
THE ROLE OF EXTERNAL EVIDENCE IN DATA MONITORING OF A CLINICAL TRIAL
Pocock, S. (1996) · Statistics in Medicine · Cited by 16
Self-citationGilpin, A. M. K., Holbrook, J. T., Jabs, D. A., & Meinert, C. L. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00268-4 · Cited by 14
Statistical approaches and policies for the operations of Data and Safety Monitoring Committees
Califf, R. M., & Ellenberg, S. S. (2001) · American Heart Journal · doi:10.1067/mhj.2001.113152 · Cited by 14
Data monitoring committees for southwest oncology group clinical trials
Green, S., & Crowley, J. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120508 · Cited by 14
Terms of reference for Data and Safety Monitoring Committees
Packer, M., Wittes, J., & Stump, D. C. (2001) · American Heart Journal · doi:10.1067/mhj.2001.113838 · Cited by 14
Data monitoring boards in the pharmaceutical industry
Herson, J. (1993) · Statistics in Medicine · doi:10.1002/sim.4780120522 · Cited by 13
Interim Analyses in Clinical Research
Berry, D. A. (1987) · Cancer Investigation · doi:10.3109/07357908709032904 · Cited by 12
Current Research in Statistical Methodology for Clinical Trials
Meier, P. (1982) · Biometrics · doi:10.2307/2529863 · Cited by 12
Data and safety monitoring committees: Philosophy and practice
Califf, R. M., & Lee, K. L. (2001) · American Heart Journal · doi:10.1067/mhj.2001.112500 · Cited by 11
Regulatory issues for Data and Safety Monitoring Committees
Fisher, L. D., & Klibaner, M. I. (2001) · American Heart Journal · doi:10.1067/mhj.2001.113839 · Cited by 9
Early stopping of prevention trials when multiple outcomes are of interest: A discussion
Green, S. B., & Freedman, L. S. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131325 · Cited by 9
The Use of Data Monitoring Committees in Clinical Trials
Ellenberg, S. S. (1996) · Drug Information Journal · doi:10.1177/009286159603000231 · Cited by 9
Monitoring and evaluating clinical trials data
Whitehead, J. (2000) · Intensive Care Medicine · doi:10.1007/s001340051123 · Cited by 8
Relationships Between Data Monitoring Committees
DeMets, D. L. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(99)00048-3 · Cited by 8
Discussion of ‘the what, why and how of bayesian clinical trials monitoring’
Machin, D. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131313 · Cited by 8
Early stopping, interim analyses, and monitoring committees: what are the tradeoffs?
Zelen, M. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.9.1314 · Cited by 8
Likelihood and clinical trials
Hill, G. B., Forbes, W., Kozak, J., & MacNeill, I. B. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00156-0 · Cited by 7
The Data and Safety Monitoring Committee: Some final thoughts
DeMets, D. L., & Yusuf, S. (2001) · American Heart Journal · doi:10.1067/mhj.2001.113837 · Cited by 7
Sheon, A. R. (1995) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1995.11.1309 · Cited by 7
Data handling in clinical trials: an ongoing debate
Jongen, P. (1995) · Multiple Sclerosis Journal · doi:10.1177/1352458519950101060 · Cited by 5
Data and Safety Monitoring Board
(1998) · Medisch-Farmaceutische Mededelingen · doi:10.1007/bf03057150 · Cited by 5
Panel discussion: The operation of data monitoring committees
(1993) · Statistics in Medicine · doi:10.1002/sim.4780120519 · Cited by 5
Data-monitoring committees in clinical trials
Sleight, P. (1993) · The Lancet · doi:10.1016/0140-6736(93)91053-o · Cited by 4
Herson, J., Ognibene, F. P., Peura, D. A., & Silen, W. (1992) · Journal of clinical research · Cited by 4
[Roaming through the methodology. XIV. The premature ending of a randomized trial].
Vandenbroucke, J. P. (1999) · PubMed · Cited by 3
Secrecy for data monitoring committees: inferior ethics, bad policy.
Wells, R. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.390 · Cited by 3
[Monitoring of clinical trials and interim analysis. 1. Monitoring committee].
Boutitie, F., Bellissant, É., Blanchard, J., Boissel, J., Cauquil, J., Chauvin, F., Derzko, G., Ducruet, T., Durrleman, S., & Jp, G. (1992) · PubMed · Cited by 3
Defending data-monitoring committees
Lancet, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)21016-6 · Cited by 3
Guidelines for data and safety monitoring committees of NASCET
Hall, Z. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380520 · Cited by 2
Are Safety Committees Really Safe?
Bergqvist, D., Forbes, C., Minder, C. E., Planès, A., & ten Cate, J. W. (1998) · Scottish Medical Journal · doi:10.1177/003693309804300205 · Cited by 2
George, S. M., Green, S., Crowley, J. J., Ellenberg, S. S., Meinert, C., Friedman, L., Brown, Pocock, S., Armitage, P., Simon, R., et al. (1993) · Statistics in Medicine · Cited by 2
Self-citationDiscussion: Jay Herson, data monitoring boards in the pharmaceutical industry
Herson, J., & Tognoni, G. (1993) · Statistics in Medicine · Cited by 2
Senn (1998) · doi:10.1002/(sici)1097-0258(19980815/30)17:15/16
Cited by
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Self-citationSPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Self-citationConsort 2010 statement: extension to cluster randomised trials
Campbell, M. K., Piaggio, G., Elbourne, D. R., Altman, D. G., & for the CONSORT Group (2012) · BMJ · doi:10.1136/bmj.e5661 · Cited by 3,510
Self-citation(2013) · European Heart Journal · doi:10.1093/eurheartj/eht150 · Cited by 2,809
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.10.001 · Cited by 2,345
Self-citation
Metadata
- Authors
- Grant, A., Altman, D., Babiker, A., Campbell, M., Clemens, F., Darbyshire, J., Elbourne, D., McLeer, S., Parmar, M., Pocock, S., Spiegelhalter, D., Sydes, M., Walker, A., & Wallace, S.
- Venue
- Health Technology Assessment
- Published
- 2005-03
- Volume
- 9
- Issue
- 7
- Pages
- 1-238, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W1993690981
- Cited by
- 269
- References
- 160
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- diamond
- Funders
- Health Technology Assessment programme (98/25/06)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.